The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which are in the same family of viruses as the Ebola virus outbreak in the Democratic Republic of the Congo. The last outbreaks of Marburg virus and Sudan ebolavirus were in Uganda, in 2017 and 2012, respectively. The Sabin Vaccine Institute will conduct nonclinical studies and complete manufacturing activities to advance the development of the vaccine candidates under a contract with HHS’s Biomedical Advanced Research and Development Authority. BARDA also is helping to develop and procure vaccines, therapeutics and diagnostics for the Ebola strain circulating in the Congo.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday updated the number of people with confirmed or probable lung injuries associated with electronic…
Headline
The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living…
Headline
The Centers for Disease Control and Prevention today released updated interim clinical guidance for U.S. health care providers evaluating and caring for…
Headline
The Centers for Disease Control and Prevention this week reported a record 2.5 million cases of chlamydia, gonorrhea and syphilis in the U.S. in 2018,…
Headline
Only one in three U.S. pregnant women receive both the flu and whooping cough vaccines as recommended, according to a Vital Signs report released today by the…
Headline
The U.S. has retained its measles elimination status for another year, the Department of Health and Human Services announced Friday.